{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,17]],"date-time":"2026-09-17T15:47:16Z","timestamp":1789660036146,"version":"4.0.1"},"reference-count":33,"publisher":"Oxford University Press (OUP)","issue":"11","funder":[{"DOI":"10.13039\/501100000024","name":"Canadian Institutes of Health Research","doi-asserted-by":"publisher","award":["143350"],"award-info":[{"award-number":["143350"]}],"id":[{"id":"10.13039\/501100000024","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":[],"published-print":{"date-parts":[[2021,12,6]]},"abstract":"<jats:title>Abstract<\/jats:title>\n                  <jats:sec>\n                    <jats:title>Background<\/jats:title>\n                    <jats:p>As new drugs are developed for multidrug-resistant tuberculosis (MDR-TB), the role of currently used drugs must be reevaluated.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Methods<\/jats:title>\n                    <jats:p>We combined individual-level data on patients with pulmonary MDR-TB published during 2009\u20132016 from 25 countries. We compared patients receiving each of the injectable drugs and those receiving no injectable drugs. Analyses were based on patients whose isolates were susceptible to the drug they received. Using random-effects logistic regression with propensity score matching, we estimated the effect of each agent in terms of standardized treatment outcomes.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Results<\/jats:title>\n                    <jats:p>More patients received kanamycin (n = 4330) and capreomycin (n = 2401) than amikacin (n = 2275) or streptomycin (n = 1554), opposite to their apparent effectiveness. Compared with kanamycin, amikacin was associated with 6 more cures per 100 patients (95% confidence interval [CI], 4\u20138), while streptomycin was associated with 7 (95% CI, 5\u20138) more cures and 5 (95% CI, 4\u20137) fewer deaths per 100 patients. Compared with capreomycin, amikacin was associated with 9 (95% CI, 6\u201311) more cures and 5 (95% CI, 2\u20138) fewer deaths per 100 patients, while streptomycin was associated with 10 (95% CI, 8\u201313) more cures and 10 (95% CI, 7\u201312) fewer deaths per 100 patients treated. In contrast to amikacin and streptomycin, patients treated with kanamycin or capreomycin did not fare better than patients treated with no injectable drugs.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Conclusions<\/jats:title>\n                    <jats:p>When aminoglycosides are used to treat MDR-TB and drug susceptibility test results support their use, streptomycin and amikacin, not kanamycin or capreomycin, are the drugs of choice.<\/jats:p>\n                  <\/jats:sec>","DOI":"10.1093\/cid\/ciaa621","type":"journal-article","created":{"date-parts":[[2020,5,23]],"date-time":"2020-05-23T00:22:17Z","timestamp":1590193337000},"page":"e3929-e3936","source":"Crossref","is-referenced-by-count":40,"title":["Aminoglycosides and Capreomycin in the Treatment of Multidrug-resistant Tuberculosis: Individual Patient Data Meta-analysis of 12 030 Patients From 25 Countries, 2009\u20132016"],"prefix":"10.1093","volume":"73","author":[{"given":"J Peter","family":"Cegielski","sequence":"first","affiliation":[{"name":"Division of Tuberculosis Elimination, Centers for Disease Control and Prevention, Atlanta, Georgia, USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Pei-Chun","family":"Chan","sequence":"additional","affiliation":[{"name":"Division of Chronic Infectious Diseases, Taiwan Centers for Disease Control, Taipei City, Taiwan"},{"name":"Institute of Epidemiology and Preventive Medicine, College of Public Health, National Taiwan University, Taipei City, Taiwan"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Zhiyi","family":"Lan","sequence":"additional","affiliation":[{"name":"Montreal Chest Institute and McGill International Tuberculosis Centre, Montreal, Quebec, Canada"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Zarir F","family":"Udwadia","sequence":"additional","affiliation":[{"name":"PD Hinduja National Hospital and Medical Research Institute, Mumbai, India"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Piret","family":"Viiklepp","sequence":"additional","affiliation":[{"name":"Estonian Tuberculosis Registry, National Institute for Health Development, Tallinn, Estonia"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jae-Joon","family":"Yim","sequence":"additional","affiliation":[{"name":"Division of Pulmonary and Critical Medicine, Department of Internal Medicine, Seoul National University College of Medicine, Seoul, South Korea"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Dick","family":"Menzies","sequence":"additional","affiliation":[{"name":"Montreal Chest Institute and McGill International Tuberculosis Centre, Montreal, Quebec, Canada"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"286","published-online":{"date-parts":[[2020,10,30]]},"reference":[{"key":"2021121022361452500_CIT0001","doi-asserted-by":"crossref","first-page":"769","DOI":"10.1136\/bmj.2.4582.769","article-title":"Streptomycin treatment of pulmonary tuberculosis: a Medical Research Council investigation","volume":"2","author":"Medical Research Council","year":"1948","journal-title":"Br Med J"},{"key":"2021121022361452500_CIT0002","volume-title":"WHO treatment guidelines for drug-resistant tuberculosis\u20142016 update","author":"World Health Organization","year":"2016"},{"key":"2021121022361452500_CIT0003","doi-asserted-by":"crossref","first-page":"429","DOI":"10.1016\/0002-9343(47)90087-9","article-title":"Streptomycin in tuberculosis","volume":"2","author":"Hinshaw","year":"1947","journal-title":"Am J Med"},{"key":"2021121022361452500_CIT0004","first-page":"S231","article-title":"Studies on the treatment of tuberculosis undertaken by the British Medical Research Council tuberculosis units, 1946\u20131986, with relevant subsequent publications","volume":"3","author":"Fox","year":"1999","journal-title":"Int J Tuberc Lung Dis"},{"key":"2021121022361452500_CIT0005","first-page":"634","article-title":"Combined report of the Veterans\u2019 Administration, Army, and Navy to the Council on Pharmacy and Chemistry of the American Medical Association: the effects of streptomycin on tuberculosis in man, preliminary statement","volume":"135","year":"1947","journal-title":"JAMA"},{"key":"2021121022361452500_CIT0006","doi-asserted-by":"crossref","DOI":"10.1111\/j.1749-6632.1958.tb54705.x","article-title":"Clinical studies of kanamycin treatment of pulmonary tuberculosis","volume":"76","author":"Donomae","year":"1958","journal-title":"Ann N Y Acad Sci"},{"key":"2021121022361452500_CIT0007","doi-asserted-by":"crossref","DOI":"10.1111\/j.1749-6632.1958.tb54725.x","article-title":"Summary of the monograph on the basic and clinical research of the new antibiotic, kanamycin","volume":"76","author":"Finland","year":"1958","journal-title":"Ann N Y Acad Sci"},{"key":"2021121022361452500_CIT0008","doi-asserted-by":"crossref","first-page":"27","DOI":"10.1159\/000386800","article-title":"The antimycobacterial activity of capreomycin","volume":"16","author":"Lucchesi","year":"1970","journal-title":"Antibiot Chemother"},{"key":"2021121022361452500_CIT0009","first-page":"1039","article-title":"Aminoglycosides. Chapter 58.","volume-title":"Goodman and Gilman\u2019s the pharmacologic basis of therapeutics","author":"MacDougal","year":"2018","edition":"13"},{"key":"2021121022361452500_CIT0010","doi-asserted-by":"crossref","first-page":"1298","DOI":"10.1128\/AAC.33.8.1298","article-title":"Comparison of bactericidal activities of streptomycin, amikacin, kanamycin, and capreomycin against Mycobacterium avium and M. tuberculosis","volume":"33","author":"Heifets","year":"1989","journal-title":"Antimicrob Agents Chemother"},{"key":"2021121022361452500_CIT0011","doi-asserted-by":"crossref","first-page":"814","DOI":"10.1164\/rccm.201604-0700OC","article-title":"Randomized trial of liposomal amikacin for inhalation in nontuberculous mycobacterial lung disease","volume":"195","author":"Olivier","year":"2017","journal-title":"Am J Respir Crit Care Med"},{"key":"2021121022361452500_CIT0012","volume-title":"World Health Organization guidelines for the management of drug-resistant tuberculosis","author":"Crofton SJ, Chaulet P, Maher D, et al","year":"1997"},{"key":"2021121022361452500_CIT0013","volume-title":"The use of bedaquiline in the treatment of multidrug-resistant tuberculosis: interim policy guidance","author":"World Health Organization.","year":"2013"},{"key":"2021121022361452500_CIT0014","volume-title":"The use of delamanid in the treatment of multidrug-resistant tuberculosis: interim policy guidance","author":"World Health Organization.","year":"2014"},{"key":"2021121022361452500_CIT0015","volume-title":"WHO consolidated guidelines on drug-resistant tuberculosis treatment","author":"World Health Organization.","year":"2019"},{"key":"2021121022361452500_CIT0016","doi-asserted-by":"crossref","first-page":"821","DOI":"10.1016\/S0140-6736(18)31644-1","article-title":"Treatment correlates of successful outcomes in pulmonary multidrug-resistant tuberculosis: an individual patient data meta-analysis","volume":"392","author":"Collaborative Group for the Meta-Analysis of Individual Patient Data in MDR-TB treatment\u20142017","year":"2018","journal-title":"Lancet"},{"key":"2021121022361452500_CIT0017","doi-asserted-by":"crossref","first-page":"e93","DOI":"10.1164\/rccm.201909-1874ST","article-title":"Treatment of drug-resistant tuberculosis. an official ATS\/CDC\/ERS\/IDSA clinical practice guideline","volume":"200","author":"Nahid","year":"2019","journal-title":"Am J Respir Crit Care Med"},{"key":"2021121022361452500_CIT0018","doi-asserted-by":"crossref","first-page":"153","DOI":"10.1016\/S1473-3099(09)70041-6","article-title":"Treatment outcomes among patients with multidrug-resistant tuberculosis: systematic review and meta-analysis","volume":"9","author":"Orenstein","year":"2009","journal-title":"Lancet Infect Dis"},{"key":"2021121022361452500_CIT0019","doi-asserted-by":"crossref","first-page":"163","DOI":"10.1111\/j.1749-6632.1958.tb54704.x","article-title":"Clinical experience with kanamycin in chronic pulmonary tuberculosis","volume":"76","author":"Bowen","year":"1958","journal-title":"Ann N Y Acad Sci"},{"key":"2021121022361452500_CIT0020","doi-asserted-by":"crossref","first-page":"88","DOI":"10.1111\/j.1749-6632.1958.tb54695.x","article-title":"Effects of kanamycin in experimental tuberculosis of guinea pigs","volume":"76","author":"Yanagisawa","year":"1958","journal-title":"Ann N Y Acad Sci"},{"key":"2021121022361452500_CIT0021","doi-asserted-by":"crossref","first-page":"103","DOI":"10.1111\/j.1749-6632.1958.tb54696.x","article-title":"The antituberculous activity of kanamycin in vitro and in the experimental animal (guinea pig)","volume":"76","author":"Steenken","year":"1958","journal-title":"Ann N Y Acad Sci"},{"key":"2021121022361452500_CIT0022","doi-asserted-by":"crossref","first-page":"157","DOI":"10.1111\/j.1749-6632.1958.tb54703.x","article-title":"Observations on the use of kanamycin in patients in a tuberculosis hospital","volume":"76","author":"Wright","year":"1958","journal-title":"Ann NY Acad Sci"},{"key":"2021121022361452500_CIT0023","first-page":"418","article-title":"Multidrug-resistant tuberculosis treatment outcomes in relation to treatment and initial versus acquired second-line drug resistance","volume":"62","author":"Cegielski","year":"2016","journal-title":"Clin Infect Dis"},{"key":"2021121022361452500_CIT0024","doi-asserted-by":"crossref","first-page":"153","DOI":"10.1016\/0041-3879(72)90012-8","article-title":"Rifampicin, ethambutol and capreomycin in pulmonary tuberculosis, previously treated with both first and second line drugs: the results of 2 years chemotherapy","volume":"53","author":"Aquinas","year":"1972","journal-title":"Tubercle"},{"key":"2021121022361452500_CIT0025","doi-asserted-by":"crossref","first-page":"105","DOI":"10.1016\/0041-3879(74)90003-8","article-title":"Treatment of isoniazid-resistant pulmonary tuberculosis with ethambutol, rifampicin and capreomycin: a co-operative study in England and Wales","volume":"55","author":"Andrews","year":"1974","journal-title":"Tubercle"},{"key":"2021121022361452500_CIT0026","doi-asserted-by":"crossref","first-page":"205","DOI":"10.1016\/S0041-3879(64)80007-6","article-title":"Treatment of pulmonary tuberculosis by capreomycin and pas: a small preliminary trial","volume":"45","author":"Cuthbert","year":"1964","journal-title":"Tubercle"},{"key":"2021121022361452500_CIT0027","doi-asserted-by":"crossref","first-page":"43","DOI":"10.1159\/000386803","article-title":"The combination of ethambutol, capreomycin, and a third drug in chronic pulmonary tuberculosis with bacterial polyresistance","volume":"16","author":"Schutz","year":"1970","journal-title":"Antibiotica et Chemotherapia"},{"key":"2021121022361452500_CIT0028","first-page":"858","article-title":"Capreomycin compared with streptomycin in original treatment of pulmonary tuberculosis. XVI. A report of the Veterans Administration-Armed Forces Cooperative. Study on the Chemotherapy of Tuberculosis","volume":"94","author":"Schwartz","year":"1966","journal-title":"Am Rev Respir Dis"},{"key":"2021121022361452500_CIT0029","first-page":"271","article-title":"Comparison of 1.0g streptomycin, 0.5g streptomycin and 1.0g capreomycin three times a week combined with PAS and isoniazid in original treatment for pulmonary tuberculosis: report of the 17th series of controlled trial of chemotherapy","volume":"51","author":"Cooperative Study Unit on Chemotherapy of Tuberculosis of the National Sanatoria in Japan","year":"1976","journal-title":"Kekkaku"},{"key":"2021121022361452500_CIT0030","first-page":"1","volume-title":"Guidelines for the programmatic management of drug-resistant tuberculosis","author":"World Health Organization.","year":"2011"},{"key":"2021121022361452500_CIT0031","doi-asserted-by":"crossref","first-page":"516","DOI":"10.1183\/09031936.00073611","article-title":"WHO guidelines for the programmatic management of drug-resistant tuberculosis: 2011 update","volume":"38","author":"Falzon","year":"2011","journal-title":"Eur Respir J"},{"key":"2021121022361452500_CIT0032","doi-asserted-by":"crossref","first-page":"e1001300","DOI":"10.1371\/journal.pmed.1001300","article-title":"Multidrug resistant pulmonary tuberculosis treatment regimens and patient outcomes: an individual patient data meta-analysis of 9153 patients","volume":"9","author":"Ahuja","year":"2012","journal-title":"PLoS Med"},{"key":"2021121022361452500_CIT0033","doi-asserted-by":"crossref","first-page":"156","DOI":"10.1183\/09031936.00134712","article-title":"Resistance to fluoroquinolones and second-line injectable drugs: impact on multidrug-resistant TB outcomes","volume":"42","author":"Falzon","year":"2013","journal-title":"Eur Respir J"}],"container-title":["Clinical Infectious Diseases"],"original-title":[],"language":"en","link":[{"URL":"http:\/\/academic.oup.com\/cid\/advance-article-pdf\/doi\/10.1093\/cid\/ciaa621\/34058048\/ciaa621.pdf","content-type":"application\/pdf","content-version":"am","intended-application":"syndication"},{"URL":"https:\/\/academic.oup.com\/cid\/article-pdf\/73\/11\/e3929\/41646865\/ciaa621.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"syndication"},{"URL":"https:\/\/academic.oup.com\/cid\/article-pdf\/73\/11\/e3929\/41646865\/ciaa621.pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2023,10,1]],"date-time":"2023-10-01T07:44:22Z","timestamp":1696146262000},"score":1,"resource":{"primary":{"URL":"https:\/\/academic.oup.com\/cid\/article\/73\/11\/e3929\/5943503"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2020,10,30]]},"references-count":33,"journal-issue":{"issue":"11","published-online":{"date-parts":[[2020,10,30]]},"published-print":{"date-parts":[[2021,12,6]]}},"URL":"https:\/\/doi.org\/10.1093\/cid\/ciaa621","relation":{},"ISSN":["1058-4838","1537-6591"],"issn-type":[{"value":"1058-4838","type":"print"},{"value":"1537-6591","type":"electronic"}],"subject":[],"published-other":{"date-parts":[[2021,12,1]]},"published":{"date-parts":[[2020,10,30]]}}}